证券代码：000756 证券简称：新华制药 公告编号：2024-25 山东新华制药股份有限公司（以下简称"公司"）于2024年4月25日召开第十一届董事会第三次 会议，审议通过了《关于会计政策变更的议案》。根据《深圳证券交易所股票上市规则》及《公司 章程》等相关规定，公司本次会计政策变更事项无需提交股东大会审议。本次会计政策变更对公司 财务状况、经营成果和现金流量不会产生重大影响。现将具体情况公告如下： 一、会计政策变更概述 1.会计政策变更的原因 2023年10月25日，财政部发布了《企业会计准则解释第17号》， 规定了"关于流动负债与非流 动负债的划分"、"关于供应商融资安排的披露"、"关于售后租回交易的会计处理"，自2024年1 月1日起施行。 2.变更前采取的会计政策 本次变更前，公司执行财政部发布的《企业会计准则——基本准则》和各项具体会计准则、企 业会计准则应用指南、企业会计准则解释公告及其他相关规定执行。 3.变更后采取的会计政策 本次变更后，公司将按照财政部发布的《企业会计准则解释第17号》要求执行。 除上述政策变更外，其他未变更部分，仍按照财政部前期颁布的《企业会计准则—基本准则》 和各项具 ...

Revenue and Profit - Revenue for Q1 2024 was CNY 2,474,697,457.66, a decrease of 6.25% compared to CNY 2,639,665,769.78 in the same period last year[7] - Net profit attributable to shareholders was CNY 141,879,437.62, down 6.41% from CNY 151,603,818.36 year-on-year[7] - Basic earnings per share decreased by 8.70% to CNY 0.21 from CNY 0.23 in the same period last year[7] - The company reported a diluted earnings per share of CNY 0.21, down 4.55% from CNY 0.22 in the same period last year[7] - Net profit for Q1 2024 was ¥145,264,098.40, a decrease of 5.03% compared to ¥154,010,414.43 in the same period last year[34] - Earnings per share for Q1 2024 were ¥0.21, down from ¥0.23 in the previous year[34] - The total comprehensive income for Q1 2024 was ¥146,079,426.17, down from ¥161,720,238.98 in the previous year[34] Cash Flow - Net cash flow from operating activities increased by 120.72% to CNY 38,063,364.43, compared to a negative cash flow of CNY 183,742,803.27 in the previous year[7] - The increase in net cash flow from operating activities was mainly due to an increase in sales collections compared to the previous year[9] - Operating cash inflow totaled CNY 2,038,794,587.41, an increase from CNY 1,768,146,489.32 year-over-year[36] - Operating cash outflow amounted to CNY 2,000,731,222.98, compared to CNY 1,951,889,292.59 in the previous period[36] - Net cash flow from operating activities was CNY 38,063,364.43, a significant recovery from a negative CNY 183,742,803.27 last year[36] - Cash inflow from financing activities was CNY 163,552,691.73, down from CNY 659,387,232.26 in the previous year[36] - Net cash flow from financing activities was CNY 16,788,795.83, recovering from a negative CNY 56,417,414.43 last year[36] - The net increase in cash and cash equivalents was CNY 6,562,677.81, contrasting with a significant decrease of CNY 297,251,460.16 last year[37] - The ending balance of cash and cash equivalents reached CNY 788,246,932.68, up from CNY 713,512,887.35 in the previous period[37] Assets and Liabilities - Total assets at the end of Q1 2024 were CNY 8,467,977,386.18, an increase of 2.19% from CNY 8,286,166,330.90 at the end of the previous year[7] - The total assets of Shandong Xinhua Pharmaceutical Co., Ltd. reached approximately CNY 8.47 billion at the end of the reporting period, an increase from CNY 8.29 billion at the beginning of the period[21] - The company's current assets totaled approximately CNY 3.48 billion, up from CNY 3.31 billion at the beginning of the period, reflecting a growth of about 4.98%[21] - The total liabilities of the company were approximately CNY 3.48 billion, down from CNY 3.51 billion, showing a decrease of about 0.9%[24] - The company reported a total of 2,441,072,309.10 in current liabilities, a decrease from 2,486,000,478.39 at the beginning of the period, indicating a reduction of about 1.8%[24] Shareholders' Equity - Shareholders' equity attributable to the parent company increased by 4.65% to CNY 4,764,918,585.13 from CNY 4,553,103,869.56 at the end of the previous year[7] - The company's equity increased to approximately CNY 682.41 million from CNY 674.68 million, reflecting a growth of about 1.0%[24] Research and Development - Research and development expenses for Q1 2024 were ¥141,905,763.44, an increase of 26.56% from ¥112,119,587.26 in the previous year[33] Stock Options - The company adjusted the stock option incentive plan, reducing the number of incentive recipients from 196 to 194 and the number of options from 23.15 million to 22.72 million[16] - The exercise price of the stock options was adjusted from CNY 7.96 to CNY 7.61 per share[16] - The first exercise period for the stock options will allow 772,480 options to be exercised starting January 15, 2024[17] Other Income and Expenses - Non-recurring gains and losses totaled CNY 4,151,982.88 for the quarter, primarily from government subsidies and asset disposals[8] - Other income for Q1 2024 was ¥22,684,697.21, significantly higher than ¥5,670,706.38 in the previous year[33] - The company reported a decrease in tax expenses to ¥23,507,423.62 from ¥30,908,896.72 in the previous year[34]

山东新华制药股份有限公司 证券代码：000756 证券简称：新华制药 公告编号：2024-26 2、为简化分红程序，董事会拟提请股东大会批准授权董事会根据股东大会决议在符合 利润分配的条件下制定并执行具体的 2024 年中期分红方案。 二、相关审批程序及相关意见 公司于 2024 年 4 月 25 日召开第十一届董事会第三次会议及第十一监事会第三次会议， 分别审议通过了《关于提请股东大会授权董事会制定并执行中期分红方案的议案》，同意将 该事项提交至股东大会审议。 三、风险提示 2024 年中期分红安排授权事项尚需经公司 2023 年度股东大会审议批准后方可生效，敬 请广大投资者注意投资风险。 关于提请股东大会授权董事会制定并执行2024年中期分红方案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 根据《上市公司监管指引第 3 号--上市公司现金分红》《上市公司自律监管指引第 1 号--主板上市公司规范运作》及《公司章程》的相关规定，为更好的回馈投资者，增强投资 者信心，结合公司经营业绩实际情况，拟定 2024 年中期分红安排如下： 一、2024 年中期 ...

证券代码：000756 证券简称：新华制药 公告编号：2024-23 山东新华制药股份有限公司 关于修订《公司章程》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈 述或重大遗漏。 （一）决定公司的经营方针和投资计划； （二）选举和更换董事，决定有关董事的报酬事项； （三）选举和更换由股东代表出任的监事，决定有关监事的报酬事项； （四）审议批准董事会的报告； （五）审议批准监事会的报告； （六）审议批准公司的年度财务预算方案、决算方案； （七）审议批准公司的利润分配方案和弥补亏损方案； （八）对公司增加或者减少注册资本作出决议； （九）对公司合并、分立、解散和清算等事项或者变更公司形式作出决议； （十）对公司发行债券作出决议； （十一）对公司聘用、解聘或者不再续聘会计师事务所作出决议； （十二）审议批准第五十八条规定的担保事项； （十三）审议公司在一年内购买、出售重大资产超过公司最近一期经审计总资产 30%的事 （十四）修改公司章程； （十五）审议代表公司有表决权的股份百分之三以上（含百分之三）的股东的提案； （十六）法律、行政法规及公司章程规定应当由股东大会作出决议的 ...

山东新华制药股份有限公司 第十一届监事会第三次会议决议公告 本公司全体监事保证信息披露内容的真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 证券代码：000756 证券简称：新华制药 公告编号：2024-21 5 名监事赞成本议案，0 票反对，0 票弃权。 三、审议通过关于提请股东大会授权董事会制定并执行 2024 年中期分红方案的议案，该议案 将提交股东大会审议。 5 名监事赞成本议案，0 票反对，0 票弃权。 备查文件 山东新华制药股份有限公司（"本公司"）第十一届监事会第三次会议通知于二零二四年四月十 日以电邮形式发出，会议于二零二四年四月二十五日在山东省淄博市高新区鲁泰大道 1 号公司会议 室召开，应到会监事 5 名，实际到会监事 5 名。会议由本公司监事会主席刘承通先生主持。会议的 召开符合有关法律、法规、规章和公司章程的规定。 会议审议并通过了以下议案： 一、审议通过本公司 2024 年第一季度报告 经审核，监事会认为董事会编制和审议本公司 2024 年第一季度报告的程序符合法律、行政法 规及中国证监会的规定，报告内容真实、准确、完整地反映了本公司的实际情况，不存在任何虚假 记载、误导性 ...

证券代码：000756 证券简称：新华制药 公告编号：2024-24 山东新华制药股份有限公司 关于提请股东大会授权董事会全权办理 以简易程序向特定对象发行股票具体事宜的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或 重大遗漏。 山东新华制药股份有限公司（"公司"）于 2024 年 4 月 25 日召开第十一届董事会第三次会议，审 议通过了《关于提请股东大会授权董事会全权办理以简易程序向特定对象发行股票具体事宜的的议 案》，该议案尚需提交股东大会审议。现将具体内容说明如下： 根据《公司法》《上市公司证券发行注册管理办法》等相关规定，公司董事会提请股东大会授权 董事会向特定对象发行融资总额不超过人民币 3 亿元且不超过最近一年末净资产 20%的股票，授权期 限为 2023 年年度股东大会审议通过之日起至 2024 年年度股东大会召开之日止。本次授权事宜包括以 下内容： 一、确认公司符合以简易程序向特定对象发行股票条件 授权董事会根据《中华人民共和国公司法》、《中华人民共和国证券法》、《上市公司证券发行注册 管理办法》及《香港联合交易所有限公司证券上市规则》等有关法律法 ...

证券代码：000756 证券简称：新华制药 公告编号：2024-20 山东新华制药股份有限公司 第十一届董事会第三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性 陈述或重大遗漏。 山东新华制药股份有限公司（"本公司"）第十一届董事会第三次会议通知于二零二四年四 月十日以电邮方式发出，会议于二零二四年四月二十五日在山东省淄博市高新区鲁泰大道 1 号 公司会议室召开，应到会董事 9 名，实际参会董事 9 名。监事会成员和非董事的副总经理列席 了会议。会议由董事长贺同庆先生主持。会议的召开符合有关法律、法规、规章和公司章程的 规定。 会议审议并通过了以下议案： 一、审议通过本公司 2024 年第一季度报告（见同日发布于《证券时报》及巨潮资讯网 （http://www.cninfo.com.cn）公告）； 9 名董事赞成本议案，0 票反对，0 票弃权。 二、审议通过了按联交所要求编制的 2023 年环境、社会及管治报告（见同日发布的巨潮资 讯网（http://www.cninfo.com.cn）H 股公告）。 9 名董事赞成本议案，0 票反对，0 票弃权。 三、审议通过 ...

Financial Performance - Operating revenue for Q1 2024 was RMB 2,474,697,457.66, a decrease of 6.25% compared to RMB 2,639,665,769.78 in Q1 2023[2] - Net profit attributable to shareholders for Q1 2024 was RMB 141,879,437.62, down 6.41% from RMB 151,603,818.36 in Q1 2023[2] - Basic earnings per share for Q1 2024 were RMB 0.21, a decrease of 8.70% from RMB 0.23 in Q1 2023[3] - The total profit for Q1 2024 was RMB 168,771,522.02, compared to RMB 184,919,311.15 in Q1 2023, showing a decline in profitability[4] - Net profit attributable to the parent company was approximately $141.88 million, a decrease from $151.60 million in the previous period[5] - Total comprehensive income attributable to the parent company was approximately $142.69 million, compared to $159.49 million previously[5] - Basic earnings per share were $0.21, down from $0.23 in the prior period[5] - Total comprehensive income for the period was approximately $146.08 million, compared to $161.72 million previously[5] - Other comprehensive income after tax attributable to the parent company was approximately $807,373.60, down from $7.89 million previously[5] - The company reported a decrease in foreign currency translation adjustments, with a loss of approximately $(69,418.40)[5] Cash Flow and Assets - Net cash flow from operating activities improved significantly to RMB 38,063,364.43, compared to a negative RMB 183,742,803.27 in the same period last year, representing a 120.72% increase[2] - Total assets as of March 31, 2024, were RMB 8,467,977,386.18, reflecting a 2.19% increase from RMB 8,286,166,330.90 at the end of 2023[3] - Net assets attributable to shareholders increased by 4.65% to RMB 4,764,918,585.13 from RMB 4,553,103,869.56 at the end of 2023[3] Research and Development - Research and development expenses for Q1 2024 were RMB 141,905,763.44, compared to RMB 112,119,587.26 in Q1 2023, indicating a focus on innovation[4] Strategic Initiatives - The company plans to continue its market expansion and enhance product development strategies in the upcoming quarters[1] - The company continues to focus on strategic initiatives to enhance operational efficiency and market presence[5] Governance and Compliance - The board approved changes to accounting policies effective January 1, 2024, with no significant impact on the financial statements[6] - The company is committed to adhering to the new accounting standards as outlined by the Ministry of Finance[6] - The board of directors consists of a mix of executive and independent non-executive members, ensuring diverse governance[7] Profitability Metrics - The company reported a gross profit margin of approximately 5.89% for Q1 2024, down from 6.81% in Q1 2023[4]

Financial Performance - The financial summary for 2023 indicates that the company achieved a total revenue of RMB 1.5 billion, representing a year-on-year increase of 12%[14] - The net profit attributable to shareholders for the year was RMB 300 million, reflecting a growth of 15% compared to the previous year[14] - Operating income for 2023 reached RMB 8.1 billion, an increase of 7.97% compared to RMB 7.5 billion in 2022[17] - Total profits for 2023 amounted to RMB 532.7 million, reflecting a growth of 12.91% from RMB 471.8 million in the previous year[17] - Net profits attributable to shareholders of the listed company increased by 20.79% to RMB 496.5 million, up from RMB 411.1 million in 2022[17] - Basic earnings per share rose to RMB 0.74, representing a 19.35% increase from RMB 0.62 in 2022[17] - The company reported a gross margin of 45%, which is an improvement from 42% in the previous year[14] - Net cash flow from operating activities decreased significantly by 65.01% to RMB 265.3 million, down from RMB 758.2 million in 2022[17] Market Expansion and Strategy - User data shows that the company expanded its customer base by 20%, reaching a total of 1.2 million active users[14] - The company has set a revenue target of RMB 1.8 billion for 2024, which would represent a growth of 20% year-on-year[14] - The company plans to expand its market presence in Southeast Asia, targeting a 15% market share by the end of 2025[14] - A strategic acquisition of a local competitor is expected to enhance the company's production capacity by 25%[14] - New product development efforts have led to the launch of three innovative pharmaceutical products, contributing to 10% of total sales in 2023[14] Shareholder Information - The total number of issued shares as of December 31, 2023, was 674,682,835, an increase from 669,627,235 in 2022[30] - The top shareholder, Hualu Holdings Group Co. Ltd., held 30.36% of the shares, totaling 204,864,092 shares[43] - The second-largest shareholder, HKSCC (Nominees) Limited, held 28.65% of the shares, totaling 193,314,147 shares[43] - The top ten shareholders collectively held a significant portion of the company's shares, with no pledges or freezes reported[44] - The company had a total of 92,982 shareholders as of February 29, 2024, indicating a slight decrease in shareholder count[39] Governance and Management - The Company has a diverse board of directors with expertise in economics, law, finance, and pharmaceuticals, enhancing its strategic decision-making capabilities[74][75][80] - The Company is focused on expanding its market presence and enhancing its product offerings through strategic leadership and experienced management[72][78] - The management team is well-versed in financial operations, with the CFO, Mr. Hou Ning, having extensive experience in auditing and finance[75] - The board's composition reflects a commitment to governance and strategic oversight, essential for the Company's long-term success[78][82] - The Company has maintained a stable leadership structure with no significant changes reported during the year[103] Internal Control and Audit - The Audit Committee confirmed that the financial statements for 2023 were prepared in accordance with the accounting policies and standards, reflecting the company's assets, liabilities, and operating results accurately as of December 31, 2023[161] - Shine Wing issued a standard audit report without reservation, indicating that the financial statements accurately represent the company's financial condition and performance for 2023[170] - The company’s governance structure includes a Remuneration and Appraisal Committee, which operates under the guidelines of the Hong Kong Stock Exchange[175] - The internal control leading team is responsible for organizing and implementing internal control activities, reporting to the Board of Directors on the development and evaluation of internal control[195] - The effectiveness of internal control may change due to internal and external environmental factors, and the company has mechanisms in place to identify and rectify internal control deficiencies[200] Employee and Training Programs - As of December 31, 2023, the Group employed 7,104 staff with total wages amounting to RMB 743,778,000[128] - In 2023, the Company completed 71 corporate-level education training programs, training a total of 3,365 employees[137] - The Company has established a training system that enhances the capability and competency of staff members, ensuring efficient operation of the management system[139] - The Group's employee remuneration is determined based on national policies and the Company's financial condition, ensuring competitive compensation[128] Proposed Dividend - The proposed dividend for the year 2023 is RMB0.25 per share, subject to shareholder approval[63] - The Company is advised to exercise caution regarding the proposed dividend distribution, which may be adjusted based on changes in total issued share capital[63] - Further details regarding the proposed cash dividend will be disclosed in due course, including payment currency and applicable foreign exchange rate[64]

证券代码：000756 证券简称：新华制药 公告编号：2024-19 山东新华制药股份有限公司 关于举办2023年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 山东新华制药股份有限公司（以下简称"公司"）已于 2024 年 3 月 29 日在巨潮资讯网 （www.cninfo.com.cn）上披露了《2023 年年度报告》及《2023 年年度报告摘要》。为便于 广大投资者更加全面深入地了解公司经营业绩、发展战略等情况，公司定于 2024 年 4 月 28 日（星期天）15:00-16:00 在"价值在线"（www.ir-online.cn）举办公司 2023 年度网上业 绩说明会，与投资者进行沟通和交流，广泛听取投资者的意见和建议。 一、参会方式 本次年度业绩说明会将采用网络互动的方式举行，投资者可于 2024 年 4 月 28 日（星期 天）15:00-16:00 通过网址 https://eseb.cn/1dNnPuxloYM 或使用微信扫描下方小程序码即 可进入参与互动交流。 二、出席人员 出席本次网上业绩说明会的人员有：董事长 ...